Genomtec started today the analysis to accelerate the planned commercialization of the Genomtec®ID platform. The analysis will include the selection of solutions to support the company’s strategic development, primarily in terms of determining the optimal time to market with the Genomtec®ID solution, including its acceleration compared to the currently announced plan.
The analysis will take into account various scenarios to accelerate the Company’s growth, including, but not limited to, the potential possible use of regulations to enable faster certification of the device, and thus faster commercialization in the marketplace.
“We expect the transitional provisions of the IVD regulation (IVDR) to be extended, which would give us the opportunity to register Genomtec®ID as an IVD device in the European Union earlier under the current Directive (IVDD), thus allowing us to start the commercialization process of our mobile POCT platform for genetic testing,” – said Miron Tokarski, CEO and co-founder of Genomtec SA.
One of the analysed options will be the optimal start of Genomtec®ID sales by the Company through commercial partners and defining the right moment for commercialization by licensing or selling the technology.
Genomtec’s current actions are aimed at accelerating the growth of the Company’s product development efforts, scaling up operations and taking advantage of the current state of market attractiveness and regulatory conditions to bring our innovation sooner to the healthcare industry.
